Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.

PMID:
18477802
2.

Novel advancements in the management of hepatocellular carcinoma in 2008.

Llovet JM, Bruix J.

J Hepatol. 2008;48 Suppl 1:S20-37. doi: 10.1016/j.jhep.2008.01.022. Epub 2008 Feb 12. Review.

PMID:
18304676
3.

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M.

Science. 2007 Jul 6;317(5834):121-4. Erratum in: Science. 2009 Dec 4;326(5958):1346.

4.

Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue.

Coudry RA, Meireles SI, Stoyanova R, Cooper HS, Carpino A, Wang X, Engstrom PF, Clapper ML.

J Mol Diagn. 2007 Feb;9(1):70-9.

5.

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.

Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM; HCC Italian Task Force.

Hepatology. 2006 Dec;44(6):1543-54.

PMID:
17133492
6.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.

Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP.

Breast Cancer Res. 2006;8(3):R25. Epub 2006 May 31.

7.

GenePattern 2.0.

Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP.

Nat Genet. 2006 May;38(5):500-1. No abstract available.

PMID:
16642009
8.

Management of hepatocellular carcinoma.

Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases.

Hepatology. 2005 Nov;42(5):1208-36. No abstract available.

PMID:
16250051
9.

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP.

Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. Epub 2005 Sep 30.

10.

Resection and liver transplantation for hepatocellular carcinoma.

Llovet JM, Schwartz M, Mazzaferro V.

Semin Liver Dis. 2005;25(2):181-200. Review.

PMID:
15918147
11.

Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays.

Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y, Fan JB.

Am J Pathol. 2004 Nov;165(5):1799-807.

12.

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS.

Hepatology. 2004 Sep;40(3):667-76.

PMID:
15349906
13.

A versatile assay for high-throughput gene expression profiling on universal array matrices.

Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, Rigault P, Zhang B, Shen R, McBride C, Li HR, Fu XD, Oliphant A, Barker DL, Chee MS.

Genome Res. 2004 May;14(5):878-85.

14.

Hepatocellular carcinoma.

Llovet JM, Burroughs A, Bruix J.

Lancet. 2003 Dec 6;362(9399):1907-17. Review.

PMID:
14667750
15.

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.

Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW.

Nat Med. 2003 Apr;9(4):416-23. Epub 2003 Mar 17.

PMID:
12640447
16.

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M.

J Hepatol. 2003 Feb;38(2):200-7.

PMID:
12547409
17.

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T.

Lancet. 2000 Sep 2;356(9232):802-7. Erratum in: Lancet 2000 Nov 11;356(9242):1690.

PMID:
11022927
18.

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H.

Hepatology. 2000 Aug;32(2):228-32.

PMID:
10915728
19.

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ.

Lancet. 1999 Mar 6;353(9155):797-801.

PMID:
10459961
20.

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group.

Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T.

N Engl J Med. 1996 Jun 13;334(24):1561-7.

Supplemental Content

Support Center